<DOC>
	<DOCNO>NCT02269605</DOCNO>
	<brief_summary>Phase I , randomize , double blind , placebo-controlled , dose-finding trial . The trialÂ´s goal evaluate two different dos Bryostatin HIV-1 latency reservoir HIV-1 infect patient receive antiretroviral treatment .</brief_summary>
	<brief_title>Bryostatin-1 Effect HIV-1 Latency Reservoir HIV-1 Infected Patients Receiving Antiretroviral Treatment</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Bryostatin 1</mesh_term>
	<criteria>Patients understand trial purpose Patients 18 50 year age Patients chronic HIV1 infection Patients receive antiretroviral treatment least 3 active drug least 2 year Undetectable viral load measure ultra sensitive method CD4+ level higher 350 cells/mm3 Patients commit use contraceptive method trial 3 month . Previous antiretroviral treatment failure , viral load outbreak undetectable HIV1 load . Low grade , transitory outbreak ( &lt; 200 RNA copies/ml ) resolve without treatment modification exclude Patients plan interrupt antiretroviral treatment trial Patients receive immunosuppressant immunostimulant drug , include valproic acid . Pregnant woman Bryostatin1 hypersensitivity Being enrol another clinical trial participate another clinical trial previous 3 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>HIV reservoir</keyword>
	<keyword>Bryostatin</keyword>
</DOC>